[co-author: Linden Thomson]

Recent notable industry transactions.

• Royal Philips announced that it has agreed to acquire Capsule Technologies, Inc., a provider of medical device integration and data technologies for hospitals and healthcare organisations, for US$635 million.
• Sanofi and Biond Biologics entered into an exclusive global licence agreement for Biond Biologics' ILT2-targeting immune checkpoint inhibitor BND-22, which is under development for the treatment of solid tumours. Biond will receive US$125 million in an upfront cash payment and is eligible to receive more than US$1 billion in potential milestone payments.
• Sanofi has agreed to acquire Kymab for an upfront payment of approximately US$1.1 billion and up to US$350 million upon achievement of certain milestones. The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action.
• PerkinElmer announced that it has agreed to acquire Oxford Immunotec at a deal value of approximately US$591 million, subject to customary closing conditions.
• Ribometrix announced a strategic collaboration with Genentech, a member of the Roche Group, to discover and develop novel RNA-targeted small molecule therapeutics against several targets, with Ribometrix receiving a US$25 million upfront payment and potential milestone payments exceeding $1 billion.
• Centene Corporation and Magellan Health entered into a merger agreement for a value of US$2.2 billion and will establish a leading behavioural health platform.
• AstraZeneca has agreed to sell the commercial rights to Atacand and Atacand Plus in around 70 countries to Cheplapharm for US$400m.
• Angelini Pharma and Arvelle Therapeutics, a Swiss-based biopharmaceutical, concluded a merger agreement under which Angelini will acquire Arvelle for a total value of up to US$960 million.
• Myovant Sciences entered a collaboration with Pfizer to develop and commercialise relugolix, a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. Myovant will be eligible to receive up to US$4.2 billion.
• Lilly had agreed to acquire Prevail Therapeutics for a total value of approximately US$1.04 billion.
• Boehringer Ingelheim has agreed to acquire NBE-Therapeutics, a clinical-stage Swiss biotech company working on antibody-drug conjugates (ADC) and cancer therapies for a transaction value of US$1.44 billion.
• Takeda Pharmaceuticals sold its primary care businesses in the Asia Pacific region to Celltrion for US$278.3 million and separately has agreed to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceu for US$322 million. Takeda also completed its sale of select prescription products to Cheplapharm for a total value of US$562 million.
• AstraZeneca has sold rights to Crestor (rosuvastatin, for the treatment of dyslipidaemia and hypercholesterolaemia) and associated medicines in certain European markets to Grünenthal for at least US$320m.
• Biogen and Sage Therapeutics have executed a collaboration and licence agreement to develop and commercialise zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for essential tremor and other neurological disorders. Sage will receive US$1.525 billion in cash, comprising an upfront payment and an equity investment in Sage, in addition to potential milestone payments.